Catalyst Pharma To Present Top-Line Results From Phase 3 Firdapse Trial

(RTTNews) - Catalyst Pharmaceutical Partners, Inc. (CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, announced that Douglas Winship, Vice President of Regulatory Operations, would present top-line safety and efficacy results from Catalyst's Phase 3 Firdapse trial at the 139th Annual Meeting of the American Neurological Association being held at The Baltimore Waterfront Marriott, October 12-14.

The presentation, entitled, "A Phase 3 Trial of Firdapse Tablets in Lambert-Eaton Myasthenic Syndrome," to be delivered at the Neuromuscular Disease Special Interest Symposia, is slated for Sunday, October 12th at 5:20 pm (EDT).